Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Beth on +44 1494 818 013 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Beth Horsley
MDD EXEC Team Leader
+44 1494 818 013

I contacted Zenopa again after a number of years, they took the time to explore what my needs were and suggested a few jobs they were recruiting for.
Bhavna, 2011

St Jude Medical initiates new FFR treatment study

16 February 2012 00:00 in Medical Company Product News

St Jude Medical has commenced a new clinical study that will aim to further demonstrate the potential benefits of fractional flow reserve (FFR)-guided treatment among heart patients.

The new study will be conducted in Japan, China, India, Korea and Australia, with the intention of assessing the health and budget impact the therapy option could have among patients with multi-vessel coronary artery disease.

FFR treatments use St Jude Medical's PressureWire Aeris or PressureWire Certus devices to measure the severity of blood flow blockages in the coronary arteries, making it easier to identify which lesions require stenting.

Previous studies conducted in Europe and the US have shown the therapy is able to deliver improved clinical outcomes, while saving money.

Frank Callaghan, president of St Jude Medical's cardiovascular division, said: "FFR represents a unique opportunity in medicine that aligns with the needs of government - to help make healthcare more affordable, and physicians - to improve care."

Last week, the company launched a new version of its Patient Care Network system, which introduces advanced remote monitoring capabilities for the first time.ADNFCR-8000103-ID-801294806-ADNFCR

Other news stories from 16/02/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd